• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Intrapleural production of interleukin 6 during mesothelioma and its modulation by gamma-interferon treatment.

作者信息

Monti G, Jaurand M C, Monnet I, Chretien P, Saint-Etienne L, Zeng L, Portier A, Devillier P, Galanaud P, Bignon J

机构信息

INSERM U131, Clamart, France.

出版信息

Cancer Res. 1994 Aug 15;54(16):4419-23.

PMID:8044791
Abstract

In vivo production of monokines was analyzed in 17 human malignant pleural mesotheliomas. High concentrations of interleukin 6 (IL-6) were detected in pleural effusions, contrasting with low levels of IL-1 beta and tumor necrosis factor alpha. This production arose from malignant cells, as shown by immunochemical analysis of pleural cells and by production of IL-6 by mesothelial cell lines. Intrapleural administration of recombinant human gamma-interferon to six patients led to a marked decrease in intrapleural IL-6 concentrations in all cases. This treatment was associated with in situ activation of macrophages and cytotoxic T-lymphocytes, as indicated by increased intrapleural neopterin and soluble CD8 concentrations. In vitro gamma-interferon had no effect on the production of IL-6 by mesothelial cell lines but decreased the growth of 3 of 6 mesothelioma cell lines. These results indicate that systemic manifestations of malignant mesothelioma, including fever, cachexia, and thrombocytosis may be related to the production of IL-6 by malignant cells, and that local gamma-interferon infusion may reduce this production by stimulating antitumoral immunity and/or by directly decreasing the proliferation of malignant cells.

摘要

相似文献

1
Intrapleural production of interleukin 6 during mesothelioma and its modulation by gamma-interferon treatment.
Cancer Res. 1994 Aug 15;54(16):4419-23.
2
Modulation of monocyte activation in patients with rheumatoid arthritis by leukapheresis therapy.白细胞分离术治疗对类风湿关节炎患者单核细胞活化的调节作用。
J Clin Invest. 1993 Mar;91(3):862-70. doi: 10.1172/JCI116307.
3
Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.腹腔注射重组干扰素-γ和重组白细胞介素2(伴或不伴肿瘤浸润淋巴细胞)对卵巢癌或腹膜癌患者的临床及生物学效应
Clin Cancer Res. 2000 Jun;6(6):2268-78.
4
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma.血管内皮生长因子是人类恶性间皮瘤中的一种自分泌生长因子。
J Pathol. 2001 Apr;193(4):468-75. doi: 10.1002/path.824.
5
Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.α-干扰素局部免疫疗法治疗转移性胸腔和腹腔积液:与免疫参数的相关性
Anticancer Res. 1996 Nov-Dec;16(6B):3855-60.
6
Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo.血小板衍生生长因子(PDGF)及其受体在人恶性间皮瘤体内外的表达
J Pathol. 1996 Feb;178(2):151-60. doi: 10.1002/(SICI)1096-9896(199602)178:2<151::AID-PATH425>3.0.CO;2-E.
7
Autocrine inhibitory influences of alpha-melanocyte-stimulating hormone in malignant pleural mesothelioma.α-黑素细胞刺激素在恶性胸膜间皮瘤中的自分泌抑制作用
J Leukoc Biol. 2004 Feb;75(2):253-9. doi: 10.1189/jlb.0603264. Epub 2003 Oct 23.
8
Inhibition of interleukin-8 reduces human malignant pleural mesothelioma propagation in nude mouse model.
Oncol Res. 1999;11(4):187-94.
9
Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting.免疫化疗可降低恶性胸膜间皮瘤的复发率:一项实验研究。
Eur J Cardiothorac Surg. 2009 Mar;35(3):457-62. doi: 10.1016/j.ejcts.2008.11.030. Epub 2009 Jan 21.
10
Control of cell cycle progression in human mesothelioma cells treated with gamma interferon.γ干扰素处理的人间皮瘤细胞中细胞周期进程的调控
Oncogene. 2001 Mar 1;20(9):1085-93. doi: 10.1038/sj.onc.1204199.

引用本文的文献

1
Targeting interleukin-6 as a treatment approach for peritoneal carcinomatosis.针对腹腔转移癌的白细胞介素-6 治疗方法。
J Transl Med. 2024 Apr 30;22(1):402. doi: 10.1186/s12967-024-05205-8.
2
Low Exposures to Amphibole or Serpentine Asbestos in Germline Bap1-mutant Mice Induce Mesothelioma Characterized by an Immunosuppressive Tumor Microenvironment.胚系 Bap1 突变小鼠低暴露于角闪石或蛇纹石石棉可诱导以免疫抑制性肿瘤微环境为特征的间皮瘤。
Cancer Res Commun. 2024 Apr 8;4(4):1004-1015. doi: 10.1158/2767-9764.CRC-23-0423.
3
Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma.
慢性炎症、氧化应激与代谢可塑性:共同驱动间皮瘤致瘤微环境的三要素。
Cells. 2023 Aug 11;12(16):2048. doi: 10.3390/cells12162048.
4
IL-27 Mediates PD-L1 Expression and Release by Human Mesothelioma Cells.白细胞介素-27介导人间皮瘤细胞程序性死亡配体-1的表达与释放。
Cancers (Basel). 2021 Aug 9;13(16):4011. doi: 10.3390/cancers13164011.
5
Biomarkers for Malignant Pleural Mesothelioma-A Novel View on Inflammation.恶性胸膜间皮瘤的生物标志物——关于炎症的新观点
Cancers (Basel). 2021 Feb 6;13(4):658. doi: 10.3390/cancers13040658.
6
The role of interleukin-6 in malignant mesothelioma.白细胞介素-6 在恶性间皮瘤中的作用。
Transl Lung Cancer Res. 2015 Feb;4(1):55-66. doi: 10.3978/j.issn.2218-6751.2014.07.01.
7
CREB-induced inflammation is important for malignant mesothelioma growth.CREB诱导的炎症对恶性间皮瘤的生长很重要。
Am J Pathol. 2014 Oct;184(10):2816-27. doi: 10.1016/j.ajpath.2014.06.008. Epub 2014 Aug 8.
8
Extracellular signal-regulated kinase 5: a potential therapeutic target for malignant mesotheliomas.细胞外信号调节激酶 5:恶性间皮瘤的潜在治疗靶点。
Clin Cancer Res. 2013 Apr 15;19(8):2071-83. doi: 10.1158/1078-0432.CCR-12-3202. Epub 2013 Feb 27.
9
Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model.在 SCID 小鼠异种移植模型中,炎症先于人类恶性间皮瘤的发展。
Ann N Y Acad Sci. 2010 Aug;1203:7-14. doi: 10.1111/j.1749-6632.2010.05554.x.
10
Expression of inducible nitric oxide synthase in healthy pleura and in malignant mesothelioma.诱导型一氧化氮合酶在健康胸膜和恶性间皮瘤中的表达。
Br J Cancer. 2000 Oct;83(7):880-6. doi: 10.1054/bjoc.2000.1384.